RxDoctor Payments Data

Craig Polinsky, MD

Internal Medicine · Boca Raton, FLNPI 1700824232

Payments from drug & device makers

$1,461in general payments, 2019–2025

Across 70 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$219
  • Novartis$176
  • Pfizer$176
  • GSK$145
  • Edwards Lifesciences$132
  • Amgen$116
  • plus $497 from 13 others

What the payments were for

  • Food & beverage$1,460100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,461 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$276,286
Medicare patients
466
Services billed
8,600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$138,393
OzempicSemaglutide53$55,697
LinzessLinaclotide30$32,548
MultaqDronedarone Hcl19$31,495
XareltoRivaroxaban24$29,932
Repatha SureclickEvolocumab31$26,411
JardianceEmpagliflozin19$22,661
MounjaroTirzepatide16$20,791
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$17,838
JanuviaSitagliptin Phosphate15$16,614
MyrbetriqMirabegron12$13,444
EntrestoSacubitril/Valsartan11$13,392
RestasisCyclosporine19$11,812
Breo ElliptaFluticasone/Vilanterol26$10,100
Rosuvastatin Calcium293$5,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$176$139,822156 claims
Novo NordiskOzempic$219$55,69753 claims
AbbVieLinzess, Restasis, Synthroid$54$48,65094 claims
GSKTrelegy Ellipta, Breo Ellipta$145$27,93849 claims
Boehringer IngelheimJardiance$15$22,66119 claims
Lilly USA, LLCMounjaro$88$20,79116 claims
MerckJanuvia$11$16,61415 claims
Astellas Pharma US IncMyrbetriq$95$13,44412 claims
NovartisEntresto$176$13,39211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →